Fate Therapeutics gets FDA green light for FT839 cell therapy trial in autoimmune diseases

By Elena MacLeod · October 2, 2026, 9:05 PM · 4 mins read

Fate Therapeutics stock jumped after the FDA cleared its FT839 cell therapy for clinical trials in several autoimmune diseases. The move puts off-the-shelf CAR T therapies in the spotlight.

Fate Therapeutics Inc (FATE) watched its shares climb 6% after the FDA cleared FT839 for clinical trials. This new cell therapy targets a wide range of autoimmune diseases. The company now has the go-ahead to start an early-stage basket trial later this year. The trial could change how off-the-shelf CAR T therapies are used.

FT839 is different from older CAR T treatments. It is built to wipe out more types of disease-causing immune cells than single-target therapies. Industry analysis shows FT839 is a dual-targeted CAR T candidate. It is engineered to hit both CD19 and CD38. The therapy uses 13 separate genetic edits. This lets it reach more harmful immune cell groups than single-target options as detailed in a Prism Market View report. Fate plans to test FT839 in rheumatoid arthritis, systemic lupus erythematosus, ANCA-associated vasculitis, and systemic sclerosis. The basket study will start enrolling patients in the second half of 2026. Fate will test FT839 both with and without conditioning chemotherapy. The company wants to make cell therapies more practical for autoimmune diseases.

FT839 is Fate Therapeutics' second CAR-T candidate for autoimmune diseases, following FT819, which is advancing toward a mid-stage trial in lupus nephritis.

Pipeline momentum and clinical ambitions

FT839 is not Fate’s first step into autoimmune cell therapy. The company’s lead candidate, FT819, is moving toward a possible mid-stage study in lupus nephritis. Early results in systemic lupus erythematosus and systemic sclerosis have been promising. Fate’s main goal is to build off-the-shelf cell therapies that can be made at scale and stored for later use. This approach avoids the tough logistics of autologous CAR T treatments, which need patient-specific cell engineering.

The FDA’s clearance for FT839 is a key regulatory step. But this is only approval to start clinical testing, not to sell the therapy. According to BioWorld, Fate can now run clinical trials, but there is no marketing approval yet. The real test will come when Fate produces strong clinical data in different autoimmune diseases. The company’s strategy follows recent progress in the CAR T field. Other engineered cell therapies have also shown breakthroughs, as reported earlier.

In October 2026, Fate Therapeutics confirmed in investor-relations materials that it continues to position itself as a clinical-stage biopharma developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, indicating that the FT839 program remains active following the July regulatory clearance.

GlobeNewswire company materials

Market reaction and retail sentiment

Retail traders showed cautious optimism. On Stocktwits, FATE stock sentiment stayed neutral in the last 24 hours. Message volume returned to normal after a spike. Some users called the FDA news "awesome." Others guessed about a possible buyout at a higher price. FATE shares have more than tripled since the start of the year. The market is hungry for progress in scalable cell therapy.

Fate Therapeutics’ FDA clearance for FT839 is a bold move in allogeneic cell therapy for autoimmune disease. The company is betting on multiple indications and large-scale manufacturing. That sets it apart from traditional autologous CAR T developers. But the real value of FT839 will depend on clinical results, not just regulatory wins or market buzz. For now, Fate has carved out a strong position in the race to bring off-the-shelf cell therapies to patients with tough autoimmune conditions.

Topics:

Biotechnology Newsroom

Elena MacLeod

Elena MacLeod is Clinical Biotechnology Editor at GenoMethods, covering CAR-T, engineered cell therapies, gene therapy, clinical trials, cancer immunology and regulatory developments. Her evidence-first reporting focuses on trial design, patient populations, safety, efficacy, response durability and the limitations that determine how early clinical results should be interpreted.